CytomX Therapeutics (CTMX) shares soared 214.7% in the last trading session to close at $5.13. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 23.8% loss over the past four weeks.Last month, the company announced the dosing of the first patient in a phase I dose-escalation study evaluating its pipeline candidate, CX-2051, in patients with advanced solid tumors. This might have driven the share price rally.This biopharmaceutical c ...

CytomX (NASDAQ:CTMX) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report.The oncology-focused biopharmaceutical company told traders that it will release its earnings report for the first quarter of 2024 when markets close on May 8, 2024. It will also host a conference call that same day starting at 5:00 p.m. Eastern Time.Investors will want to keep an eye on EPS and revenue as two important metrics in this earnings report. Wall Street ...

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer typ ...

- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies' TCB collaboration with Astellas, triggering a $5 million milestone payment ...

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad CytomX-Astellas alliance on T-cell engaging bispecifics - - CytomX retains option for US co-commercialization and economic rights for certain programs - SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally acti ...

CytomX Therapeutics (NASDAQ:CTMX) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report.The CytomX Therapeutics earnings report notes that the company spent most of 2023 cutting costs to continue operations. That saw its 2023 operating expenses come in at $107.7 million as compared to $154.5 million in 2022.CytomX Therapeutics notes that a large portion of these savings came from a workforce reduction in 2022. That resulted ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Joe Catanzaro - Piper Sandler Malcolm Kuno - JPMorgan Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen only-mode. ...

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced earnings of $0.04, delivering a surprise of 123.53%.Over the last four quarter ...

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) anticipated in the 1st half of 2024 - - CX-801 (IFNα2b) Phase 1 clinical study initiation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma anticipated in 1st half of 2024 -   - Management to hold conference call today at 5 p.m. EDT / 2 p.m. ...

Exhibit 99.1 CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., March 11, 2024 – CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update. "2023 was a year of sustained execution across our pipeline, highlighted by the continued progress of CX-904 in Phase 1 dose escalation and the parallel advancement of CX-2051 and ...